Home › Chronische lymfatische leukemie › Illinois › Chicago
Chronische lymfatische leukemie klinische studies in Chicago, IL
14 studies voor Chronische lymfatische leukemie zoeken deelnemers op locaties in en rond Chicago (binnen ongeveer 30 mijl). Open een studie om te zien wie er kan deelnemen en hoe je contact opneemt met het studieteam.
Officiële studietekst (Engels)
Rekruteren voor een studie? Laat deze bovenaan deze pagina verschijnen — $99 voor 30 dagen →
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
RekruterenFase 3
- Northwestern University, Chicago
- University of Illinois, Chicago
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RekruterenObservatieonderzoekGezonde vrijwilligers welkom
- Mount Sinai Hospital Medical Center, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- University of Illinois, Chicago
- en nog 1
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
RekruterenFase 3
- Northwestern University, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
RekruterenFase 3
- Northwestern University, Chicago
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
RekruterenFase 3
- Northwestern University, Chicago
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
RekruterenFase 3
- University of Chicago Medical Center, Chicago
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
RekruterenFase 1
- The David and Etta Jonas Center for Cellular Therapy, Chicago
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
RekruterenFase 1
- Northwestern University, Chicago
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
RekruterenFase 1
- University of Chicago, Chicago
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
RekruterenFase 1/2
- University of Illinois at Chicago Cancer Center, Chicago
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
RekruterenFase 1
- The University of Chicago Medical Center, Chicago
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
RekruterenFase 4
- Northwestern University, Chicago
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
RekruterenFase 4
- Northwestern University, Chicago
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
RekruterenFase 1
- Northwestern Memorial Hospital, Chicago
Chronische lymfatische leukemie studies in andere steden
- Boston, MA31 studies
- Columbus, OH28 studies
- Durham, NC27 studies
- Washington, DC22 studies
- Seattle, WA20 studies
- Rochester, MN19 studies
- New York City, NY18 studies
- Houston, TX17 studies
- Baldwin Park, CA16 studies
- Milwaukee, WI15 studies
- Cincinnati, OH14 studies
- Nashville, TN13 studies
Andere studies in Chicago
- Niet-kleincellige longkanker61 studies
- Borstkanker58 studies
- Kanker (alle vormen)51 studies
- Metastatische kanker45 studies
- Prostaatkanker45 studies
- Obesitas41 studies
- Longkanker41 studies
- Eierstokkanker36 studies
- Beroerte34 studies
- Colorectale kanker33 studies
- Hartfalen31 studies
- Overgewicht28 studies
Van ClinicalTrials.gov, gegevens opgehaald op 5 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.